Open company graph database — free web & API
ログイン

Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences別名
銘柄コード
上場市場
NASDAQ
国
United States of America
従業員(単独)
416
関連会社
5
§01

基本情報

BASIC
所在地
10770 Wateridge Circle, Suite 200 San Diego, California 92121 United States
社長
Bernd Brust
従業員数(単独)
416 人
従業員数(連結)
開始日
2014-01-01
終了日
§02

サイト

1 DOMAINS
§03

事業内容

17
complex nucleic acids for vaccine, therapeutic and diagnostic applicationscustom enzymes for research and diagnostic useantibody-based products to detect impurities during the production of biopharmaceutical productsRNA synthesis and scale up, including mRNA production, yield-enhancing proprietary CleanCap® mRNA caspecialty reagents for DNA and RNA oligonucleotide synthesis for a broad range of applicationsbioprocess impurity detection, process-related impurity analytics and viral clearance prior to humanmolecular biology enzymes used in the fields of molecular diagnostics and nucleic acid therapieshelping deliver novel vaccines, therapeutics and diagnosticsRNA synthesis and scale up, including mRNA productionCleanCap® mRNA capping technologyCDMO services ranging from research to GMP gradesSpecialty reagents for DNA and RNA oligonucleotide synthesisBioprocess impurity detection, process-related impurity analytics and viral clearanceMolecular biology enzymes used in molecular diagnostics and nucleic acid therapiesComplex nucleic acids for vaccine, therapeutic and diagnostic applicationsCustom enzymes for research and diagnostic useAntibody-based products to detect impurities during biopharmaceutical production
§04

関連会社

5 COMPANIES
会社名 Group 親会社 子会社 得意先 仕入先 業務提携 銀行等 株主等
Alphazyme
Group
Cygnus Technologies
Group
Glen Research
Group
TriLink BioTechnologies
Group
Equiniti Trust Company, LLC
仕入先
リンク無しの社名は OpenBizGraph 未登録企業
§05

関連図

NETWORK
ドラッグで移動 · クリックで詳細へ
§06

沿革

1 EVENTS

Cygnus Technologies Report出典

§07

ニュース

12 ARTICLES

Maravai LifeSciences Reports Q3 2026 Financial Results出典

Maravai LifeSciences Holdings, Inc. announced its financial results for the third quarter ended September 30, 2026. Total revenue increased 10% year-over-year, while mRNA revenue grew 28%. The company highlighted its continued growth in life science reagents and services to researchers and biotech innovators.

November 2026 Investor Conferences出典

Maravai LifeSciences announced its November investor conference schedule. CFO Raj Asarpota is scheduled to join a fireside chat at the Stifel Healthcare Conference in New York on November 12 at 10:40 a.m. EST; the announcement also begins listing a November 17 appearance at 4:00 p.m. GMT, but the remaining details are cut off.

Maravai to Host Q3 2026 Earnings Call出典

Maravai LifeSciences plans to announce its third-quarter 2026 financial and operating results after market close on November 4, 2026. It will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET).

TriLink Wins China CleanCap Patent出典

TriLink BioTechnologies has been granted an additional patent in China for its CleanCap technology. The patent protects CleanCap cap analog compounds and mRNA-based pharmaceutical compositions, extending coverage beyond method claims.

Maravai to Host Aug. 6 Earnings Call出典

Maravai LifeSciences plans to announce its second-quarter 2026 financial and operating results after the market closes on Thursday, August 6. The company will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET).

Maravai Reports Q2 2026 Results出典

Maravai LifeSciences reported financial results for the second quarter ended June 30, 2026. Total revenue increased 9% from the prior-year quarter.

TriLink Secures Chinese CleanCap Patent出典

TriLink BioTechnologies, a Maravai LifeSciences company, received a new patent from China’s CNIPA covering methods of synthesizing RNA. The company says its complete portfolio of CleanCap® analogs is patented in major jurisdictions and that it is the sole authorized manufacturer of the analogs.

TriLink Opens GMP Enzyme Facility出典

TriLink, part of Maravai LifeSciences, opened a GMP enzyme manufacturing facility in Jupiter, Florida. The facility is designed to give RNA therapeutics developers coordinated access to key manufacturing materials from one supplier, simplifying sourcing and supporting more efficient production scale-up.

Maravai refinances credit agreement through 2032出典

Maravai LifeSciences announced that certain subsidiaries entered into a new credit agreement with a $150 million term loan facility and a $30 million revolving credit facility. The term loan, together with approximately $98.5 million in cash on hand, was used to prepay borrowings under the prior agreement. The refinancing extends the maturity to 2032.

Maravai to Attend Jefferies Conference出典

Maravai LifeSciences announced that CFO Raj Asarpota will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on June 4, 2026, at 12:50 p.m. Eastern Time. A live webcast will be available on the company’s Investor Relations website.

§09

出典・更新

SOURCES
↑